EquityBites - Dec. 24, 2010
Clinical-stage biopharmaceutical company Dynavax Technologies Corporation (Nasdaq:DVAX) on Thursday reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine.
The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection.
The company said that the Phase 1b data showed that all doses were generally safe and well tolerated. Also, individual immunologic and virologic responses were observed across cohorts at all dose levels.
No conclusions regarding the potential clinical impact of the therapy could be reached in this small study.
The company's candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.
Source
No comments:
Post a Comment